Table 2.
CA1 concentrations of GluN2B-containing NMDA receptor, PSD95 and GAD protein. Group average +/− standard error of the mean
The CA1 concentrations of the three target proteins altered in CA3. In CA1 tissue, GluN2B-containing NMDA receptor, PSD95, or GAD67 were not altered in SZ, in either the whole cohort or in the off medication SZ cohort subgroup; primary comparisons were not significant with the bonferroni correction.
PROTEIN | HC(all) | SEM(±) | SZ(all) | SEM(±) | p | HC(*) | SEM(±) | SZ(OFF) | SEM(±) | p |
---|---|---|---|---|---|---|---|---|---|---|
GluN2B/GluN1 | 0.56 | 0.08 | 0.65 | 0.09 | 0.34 | 0.64 | 0.11 | 0.64 | 0.08 | 0.99 |
PSD95 | 1.46 | 0.23 | 2.05 | 0.16 | 0.084 | 1.75 | 0.37 | 1.91 | 0.22 | 0.72 |
GAD67 | 0.86 | 0.04 | 0.83 | 0.04 | 0.70 | 0.88 | 0.05 | 0.79 | 0.08 | 0.31 |
these HC are the subgroup of HC paired with the SZ off medication cases.
HC(all), N= 21; SZ(all), N=21; HC(*), N=11; SZ(off), N=11